Zyvox, Synercid Launches Indicate Market Receptivity To New Antibiotics
Executive Summary
Pharmacia's Zyvox (linezolid) sales of $19 mil. in the two-and-a-half months from its U.S. commercial launch in mid-April until the end of the June 30 quarter put the product $4 mil. ahead of sales of the Aventis antibiotic Synercid (quinipristin/dalfopristin) in the second quarter of 2000.
You may also be interested in...
Cubist Cidecin NDA For Mid-2002; Launch Will Need Up To 150 Reps, CEO Says
Cubist's will file an NDA for its intravenous antibiotic Cidecin (daptomycin) in mid-2002, CEO Scott Rocklage told analysts during Bear Stearns' "virtual" healthcare conference Sept. 24.
Cubist Cidecin NDA For Mid-2002; Launch Will Need Up To 150 Reps, CEO Says
Cubist's will file an NDA for its intravenous antibiotic Cidecin (daptomycin) in mid-2002, CEO Scott Rocklage told analysts during Bear Stearns' "virtual" healthcare conference Sept. 24.
Cubist Changes Internet Press Release Policy After FDA Letter On Daptomycin
Cubist Pharmaceuticals will purge press releases from its website after six months in response to a Nov. 22 letter from FDA maintaining that Cubist's press releases available on the Internet amount to pre-approval promotion of Cidecin (daptomycin).